Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01307267 · ClinicalTrials.gov registry record · Phase 1

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Lymphoma, Non-Hodgkin, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
190
Enrollment target
20
Study locations

NCT01307267 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Lymphoma, Non-Hodgkin that has completed, run by Pfizer. The registered enrollment target is 190 participants, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01307267, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Lymphoma, Non-Hodgkin, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
190 participants
Enrollment target
20
Study locations

Study Summary

A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).

Conditions Studied

Carcinoma, Non-Small Cell Lung Lymphoma, Non-Hodgkin Carcinoma, Renal Cell Malignant Melanoma Lymphoma, Large B-Cell, Diffuse Lymphoma, Follicular Carcinoma, Squamous Cell of Head and Neck

Interventions

  • DRUG rituximab
  • DRUG PF-05082566

Study Locations (20)

California

  • City of Hope - Duarte
  • UC San Diego Moores Cancer Center-Investigational Drug Services - La Jolla
  • UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Hospital) - La Jolla
  • UC San Diego Moores Cancer Center - La Jolla
  • Research Administration Office: Clinical Research Unit - Los Angeles
  • Ronald Reagan UCLA Medical Center, Drug Information Center - Los Angeles
  • UCLA Bowyer Clinic - Los Angeles
  • UCLA Hematology-Oncology Clinic - Los Angeles
  • Stanford University Medical Center - Palo Alto
  • Stanford University Medical Center - Palo Alto
  • UC San Diego Medical Center - Hillcrest - San Diego
  • Santa Monica UCLA Hematology & Oncology Clinic - Santa Monica
  • Stanford University Medical Center - Stanford

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Emory University Hospital - Atlanta
  • The Emory Clinic, Building A - Atlanta
  • The Emory Clinic - Atlanta
  • Winship Cancer Institute - Atlanta

District of Columbia

  • Georgetown University Medical Center Department of Pharmacy, Research - Washington D.C.
  • MedStar Georgetown University Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2011-06-21
Est. Completion 2019-02-20
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01307267

The ClinicalTrials.gov registry entry for NCT01307267 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (41% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which rituximab is the first listed.

NCT01307267 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Georgia, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT01307267 about?

NCT01307267 is a clinical study titled "A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab". A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).

What is the current status of trial NCT01307267?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 190 participants. The study started on 2011-06-21. Estimated completion is 2019-02-20.

What conditions does trial NCT01307267 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Lymphoma, Non-Hodgkin, Carcinoma, Renal Cell, Malignant Melanoma, Lymphoma, Large B-Cell, Diffuse.

What interventions are being tested in trial NCT01307267?

The interventions under investigation include: rituximab (DRUG), PF-05082566 (DRUG).

Who is sponsoring clinical trial NCT01307267?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01307267 being conducted?

This trial has 20 study locations across California, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Lymphoma, Non-Hodgkin

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.